ACM
AUTL

Aubrey Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Aubrey Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-130,000
Closed -$180K – 43
2026
Q1 		$180K Sell
130,000
-95,201
-42% -$145K 0.1% 50
2025
Q4 		$445K Sell
225,201
-9,253
-4% -$14.2K 0.18% 52
2025
Q3 		$375K Sell
234,454
-217,746
-48% -$425K 0.12% 51
2025
Q2 		$1.05M Buy
452,200
+332,202
+277% +$549K 0.38% 35
2025
Q1 		$197K Buy
119,998
+35,176
+41% +$71.4K 0.08% 51
2024
Q4 		$199K Buy
+84,822
New +$287K 0.08% 50

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Aubrey Capital Management's AUTL Position: Q2 2026 in Review

Aubrey Capital Management sold out of Autolus Therapeutics (AUTL) in Q2 2026, closing a stake of 130,000 shares — an estimated $180K sold.

Aubrey Capital Management first reported a position in AUTL in Q4 2024 and held it in 6 quarters. The position peaked at $1.05M in Q2 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Aubrey Capital Management reported no remaining Autolus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Aubrey Capital Management sold 130,000 Autolus Therapeutics shares in Q2 2026, an estimated $180K.
  • Aubrey Capital Management first reported a position in Autolus Therapeutics in Q4 2024 and held it in 6 quarters.
  • Aubrey Capital Management's Autolus Therapeutics position peaked at $1.05M in Q2 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Aubrey Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.